Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients
view all Clinical Trials
Overview
This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized mild or moderately symptomatic COVID-19 patients with a parallel non-randomized Control Arm for treatment with standard of care only.
Contact
For more information about this trial or to inquire about eligibility, email breathe@tuhs.temple.edu or call 215-707-1359.